# PARP inhibition in cancer therapy

{
  "id": "T11914",
  "title": "PARP inhibition in cancer therapy",
  "url": "/topics/T11914",
  "kind": "topic-directory",
  "aeo_cohort": "topic-directory",
  "provider": "openalex",
  "revision": "c4785f61e12ddb8c",
  "catalogue_revision": "f050b5d4780b1289",
  "numeric_address": "36249527203848674",
  "address_version": "morton4x16-v1",
  "coordinates": [
    4,
    27,
    2730,
    11914
  ],
  "answer_status": "Directory metadata; local answer requires separate source review",
  "truth_status": "Subject descriptor, not a factual answer or a demonstrated knowledge gap"
}

This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored.

Directory metadata is not a factual answer or evidence of a global knowledge gap.

Source: https://openalex.org/T11914

No owner-reviewed local answer yet.